179 related articles for article (PubMed ID: 17709468)
1. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.
Chou S; Marousek GI; Van Wechel LC; Li S; Weinberg A
Antimicrob Agents Chemother; 2007 Nov; 51(11):4160-2. PubMed ID: 17709468
[TBL] [Abstract][Full Text] [Related]
2. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Scott GM; Weinberg A; Rawlinson WD; Chou S
Antimicrob Agents Chemother; 2007 Jan; 51(1):89-94. PubMed ID: 17043128
[TBL] [Abstract][Full Text] [Related]
3. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.
Marfori JE; Exner MM; Marousek GI; Chou S; Drew WL
J Clin Virol; 2007 Feb; 38(2):120-5. PubMed ID: 17157554
[TBL] [Abstract][Full Text] [Related]
4. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.
Chou S; Marousek G; Li S; Weinberg A
J Clin Virol; 2008 Sep; 43(1):107-9. PubMed ID: 18502683
[TBL] [Abstract][Full Text] [Related]
5. Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Chou S; Marousek G; Bowlin TL
Antimicrob Agents Chemother; 2012 Jan; 56(1):197-201. PubMed ID: 21968367
[TBL] [Abstract][Full Text] [Related]
6. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.
Chou S
J Clin Virol; 2011 Apr; 50(4):287-91. PubMed ID: 21295516
[TBL] [Abstract][Full Text] [Related]
8. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus.
Chou S; Lurain NS; Thompson KD; Miner RC; Drew WL
J Infect Dis; 2003 Jul; 188(1):32-9. PubMed ID: 12825168
[TBL] [Abstract][Full Text] [Related]
9. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
James SH; Price NB; Hartline CB; Lanier ER; Prichard MN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3321-5. PubMed ID: 23650158
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Fischer L; Laib Sampaio K; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2013 Dec; 100(3):575-7. PubMed ID: 24120366
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
[TBL] [Abstract][Full Text] [Related]
12. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.
Mousavi-Jazi M; Schloss L; Drew WL; Linde A; Miner RC; Harmenberg J; Wahren B; Brytting M
J Clin Virol; 2001 Dec; 23(1-2):1-15. PubMed ID: 11595579
[TBL] [Abstract][Full Text] [Related]
13. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Chou S; Marousek GI
J Virol; 2008 Jan; 82(1):246-53. PubMed ID: 17942550
[TBL] [Abstract][Full Text] [Related]
14. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.
Chou S; Van Wechel LC; Lichy HM; Marousek GI
Antimicrob Agents Chemother; 2005 Jul; 49(7):2710-5. PubMed ID: 15980340
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism of drug-resistance in human cytomegalovirus].
Eizuru Y
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():476-9. PubMed ID: 17455666
[No Abstract] [Full Text] [Related]
16. Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
Chou S
Antiviral Res; 2017 Feb; 138():57-60. PubMed ID: 27940027
[TBL] [Abstract][Full Text] [Related]
17. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.
Chou S; Miner RC; Drew WL
J Infect Dis; 2000 Dec; 182(6):1765-8. PubMed ID: 11069251
[TBL] [Abstract][Full Text] [Related]
18. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy.
Chou S; Marousek G; Parenti DM; Gordon SM; LaVoy AG; Ross JG; Miner RC; Drew WL
J Infect Dis; 1998 Aug; 178(2):526-30. PubMed ID: 9697736
[TBL] [Abstract][Full Text] [Related]
19. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
20. Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.
Gilbert C; Azzi A; Goyette N; Lin SX; Boivin G
Antimicrob Agents Chemother; 2011 Sep; 55(9):4019-27. PubMed ID: 21709106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
